Opinion

Video

Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer shows darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.

Timecodes

1:30 ARIs in Prostate Cancer

7:40 Experience with ARIs in PC

12:05 Use of PC RWD in Practice

16:00 DEAR Study in nmCRPC

20:55 DEAR Race Subgroup Analysis

25:00 Other ARI RWD in nmCRPC

27:45 Interpreting & Using RWD

Related Videos
1 expert in this video
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
4 experts in this video
© 2025 MJH Life Sciences

All rights reserved.